|Bid||1.61 x 1200|
|Ask||1.62 x 800|
|Day's Range||1.59 - 1.63|
|52 Week Range||1.34 - 2.88|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Chesterbrook, Pennsylvania-based company said it had a loss of 13 cents per share. The biopharmaceutical company posted revenue of $2.5 million in the period. The company's shares closed at $1.49. ...
Trevena (NASDAQ: TRVN) is expecting an FDA decision on its pain drug oliceridine on November 2. Furthermore, the FDA has informed the company that it intends to convene an advisory committee meeting to discuss the oliceridine filing (likely in September), which could be a catalyst for shares if positive. Wall Street analysts continue to believe Olinvo will likely be approved by the FDA based on the draft guidelines and two positive pivotal Phase 3 APOLLO studies and ATHENA safety study.
Trevena (NASDAQ:TRVN) and Array Biopharma (NASDAQ:ARRY) investors could be celebrating soon enough, should these two drug makers achieve that triumphant FDA approval at the close of a winding biotech road. Between Trevena's opioid asset oliceridine, designed as an intravenous treatment of severe acute pain, and Array's BRAF-mutant melanoma combination therapy candidate encorafenib + binimetinib getting close to final FDA verdicts, two bulls at Cowen are out shedding light on the opportunity ahead. By Cowen's bet, these drug makers are steaming ahead to stamps of FDA approval.
Investors seeking to increase their exposure to growth should consider companies such as Trevena and Redfin. Analysts are generally optimistic about the future of these stocks, based on how muchRead More...
The licensing deal for rights to the Chester County's company opioid pain medicine with a new mechanism of action includes a $2.5 million upfront payment.
The Chesterbrook, Pennsylvania-based company said it had a loss of 14 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
The deal involves Trevena experimental pain medicine Olinvo, which it is developing as a safer alternative to traditional opioids. The FDA is reviewing a new drug application Trevena filed last year to market the drug in the United States.
The former GlaxoSmithKline executive has led the company, which is working on a new type of pain medicine, for the past decade. Her successor will be promoted from within the company.
On a per-share basis, the Chesterbrook, Pennsylvania-based company said it had a loss of 24 cents. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Trevena Inc’s (NASDAQ:TRVN): Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The US$120.24M market-cap company’s lossRead More...
The company will next report results on Feb. 9, before the bell. Analysts are looking for earnings of 44-cents-per-share on revenues of $4 billion. When the company last reported on Nov. 10, a loss of 33-cents-per-share beat estimates by 10 cents on a 1.8% decline in revenues.
Trevena saw its shares make a handy gain to start out Wednesday after the firm announced that the FDA accepted its most recent NDA for Olinvo.
Several companies made headlines after hours Tuesday, including Moneygram International Inc (NASDAQ:MGI), Trevena Inc (NASDAQ:TRVN) and Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Moneygram International’s big-money deal did not go through. This isn’t the first deal between a Chinese party and the U.S. that was rejected by the administration of U.S. President Donald Trump.
The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.
Chester County biopharmaceutical company Trevena Inc. is cutting 21 jobs and halting its investments in early-stage research under a restructuring to focus its resources on its lead new drug candidate. The workforce reduction represents 30 percent of the Chesterbook, Pa., company's staff. Trevena's immediate focus will be on the potential approval and commercialization of Olinvo, its new drug candidate under development as a potential treatment to manage moderate-to-severe acute pain.